Search

Luca Richeldi,1 Pietro Schino,2 Elena Bargagli,3 Alberto Ricci,4 Alberto Rocca,5 Francesca Marchesani,6 Alfio Pennisi,7 Gianna Camiciottoli,8,9 Maria D’Amato,10 Francesco Macagno,1 Ulrica Scaffidi Argentina,11 Eleonora Ingrassia,11 Alessio Piraino11 1Division of Pulmonary Medicine, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy; 2Miulli Hospital, Acquaviva Delle Fonti, Bari, Italy; 3Respiratory Diseases Unit, Department of Medical and Surgical Sciences, Neuro Sciences, Siena University Hospital, Siena, Italy; 4Department of Medical-Surgical Sciences and Translational Medicine, Via di Grottarossa 1035, Sapienza University of Rome, Rome, Italy; 5Department of Respiratory Medicine, Bellaria Hospital, Bologna, Italy; 6Division of Pneumology, Ospedale di Macerata, Macerata, Italy; 7Department of Respiratory Medicine, Hospital Clinic “Casa di Cura Riabilitativa Calaciura”, Catania, Italy; 8Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy; 9Department of Cardiothoracovascular, Careggi University Hospital, Firenze, Italy; 10UOSD Malattie Respiratorie ”Federico II”, Ospedale Monaldi, Napoli, 80131, Italy; 11Medical Affairs, Chiesi Italia S.p.A, Parma, ItalyCorrespondence: Ulrica Scaffidi Argentina, Chiesi Italia S.P.A, Via Giacomo Chiesi 1, Parma, 43122, Italy, Tel +39 0521 1689690 ; +39 346 82 61 074, Email u.scaffidiargentina@chiesi.comPurpose: The TRITRIAL study assessed the effects of beclometasone dipropionate/formoterol fumarate/glycopyrronium (BDP/FF/G) fixed combination in patients with chronic obstructive pulmonary disease (COPD) in a real-world setting, focusing on patient’s experience and perspective through the use of patients reported outcomes.Patients and Methods: TRITRIAL was a multicenter, prospective, observational study conducted on patients with moderate-severe C

Purpose: The TRITRIAL study assessed the effects of beclometasone dipropionate/formoterol fumarate/glycopyrronium (BDP/FF/G) fixed combination in patients with chronic obstructive pulmonary disease (COPD) in a real-world setting, focusing on patient's experience and perspective through the use of patients reported outcomes. Patients and methods: TRITRIAL was a multicenter, prospective, observational study conducted on patients with moderate-severe COPD treated with BDP/FF/G fixed therapy for 12 months. The main objective was to evaluate the impact of BDP/FF/G on health status through the COPD Assessment Test (CAT) score. Additional assessments included adherence and satisfaction, measured by the TAI-10/12 questionnaire and a specifically designed eight-item questionnaire, quality of life through the EQ-5D-5L test, sleep quality through the COPD and Asthma Sleep Impact Scale (CASIS), as well as safety and disease-related outcomes. Results: Data from 655 patients were analyzed in the study. The mean total CAT score significantly improved (from 22.8 at baseline to 18.1 at 6 months and 16.5 at 12 months; p < 0.0001), as well as all the eight CAT sub-items, which decreased on average by 0.5-0.9 points during the study. Adherence and usability of the inhaler also improved during the study, with a decrease in poor compliance (from 30.1% to 18.3%) and an increase in good compliance (from 51.8% to 58.3%) according to the TAI score. Patients also benefited from significantly improved quality of life (EQ Index from 0.70 to 0.80; EQ-5D VAS score from 55.1 to 63.1) and sleep quality (CASIS score from 41.1 to 31.8). Finally, patients reported a significant reduction in exacerbation during the study. Conclusion: TRITRIAL showed that the BDP/FF/G fixed combination is effective and safe in patients with moderate-severe COPD and poorly controlled disease, improving patients' HRQoL, sleep quality, adherence and inhaler usability and reducing COPD symptoms and the risk of exacerbati

Eleonora Volpato,1– 3 Stefano Centanni,4 Paolo Banfi,3 Salvatore D’Antonio,5 Enrico Peterle,6 Filomena Bugliaro,7 Ignazio Grattagliano,8 Alessio Piraino,9 Luca Cavalieri,9 Alfio Pennisi,10 Gianluca Danesi,11 Luigi Santoiemma,12 Maria Giulia Marini1 1Healthcare Area, ISTUD Foundation, Milan, Italy; 2Department of Psychology, Università Cattolica del Sacro Cuore, Milan, Italy; 3Heart-Respiratory Rehabilitation Unit, IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy; 4Department of Health Sciences Università degli Studi di Milano - Respiratory UnitASST Santi Paolo e Carlo, Milan, Italy; 5Associazione ONLUS BPCO, Rome, Italy; 6General Practitioner, Local Health Department 3 Serenissima, Venezia, Italy; 7Federasma e Allergie-Federazione Italiana Pazienti OdV, Prato, Italy; 8Italian College of General Practitioners, Bari, Italy; 9Chiesi Farmaceutici S.p.A, Parma, italy; 10Rehabilitation Clinic Monsignor Calaciura Biancavilla, Catania, Italy; 11Local Health Department Romagna Pulmonology Ravenna, Ravenna, Italy; 12General Practitioner, Local Health Department Bari, Bari, ItalyCorrespondence: Eleonora Volpato Email evolpato@istud.itPurpose: The COVID-19 pandemic has disrupted many lives, including those of people suffering from chronic obstructive pulmonary disease (COPD) and their caregivers. The main aim of this study was to use narrative medicine, a validated approach promoting quality of care to explore how the COVID-19 pandemic impacted the quality of care, quality of life, psychological factors and social factors of people affected by COPD and their caregivers and healthcare professionals (HCPs). A secondary aim was to explore the role of telemedicine in combating isolation and providing access to care.Methods: A cross-sectional observational narrative medicine study was conducted between July and November 2020 across Italy. An online semi-structured questionnaire with a narrative plot was completed by 146 participants (79 COPD patients, 24 caregivers, and 43 HCP

Riccardo Polosa,1–3,* Jaymin Bhagwanji Morjaria,4,5,* Umberto Prosperini,6 Cristina Russo,7 Alfio Pennisi,8 Rosario Puleo,1–3 Massimo Caruso,1,2 Pasquale Caponnetto1,2 1Department of Clinical & Experimental Medicine, University of Catania, Catania, Italy; 2Centre for the Prevention and Treatment of Tobacco Addiction (CPCT), Teaching Hospital “Policlinico – V. Emanuele”, University of Catania, Catania, Italy; 3Institute of Internal and Emergency Medicine, Teaching Hospital “Policlinico – V. emanuele”, University of Catania, Catania, Italy; 4Department of Respiratory Medicine, Royal Brompton & Harefield Hospital Foundation Trust, Harefield Hospital, Harefield, UK; 5Imperial College, Harefield, UK; 6Hospital “San Vincenzo”, Taormina, Italy; 7Emergency Department, Hospital “Arnas Garibaldi”, Catania, Italy; 8Department of Respiratory Medicine, Private clinics “Musumeci-Gecas”, Catania, Italy *These authors contributed equally to this work Background: Health effects of electronic cigarette (EC) use in patients with chronic obstructive pulmonary disease (COPD) are largely unexplored.Aim: We present findings from a long-term prospective assessment of respiratory parameters in a cohort of COPD patients who ceased or substantially reduced conventional cigarette use with ECs.Methods: We prospectively re-evaluated COPD exacerbations, spirometric indices, subjective assessments (using the COPD Assessment Tool [CAT] scores), physical activity (measured by the 6-minute walk distance [6MWD]), and conventional cigarette use in EC users with COPD who were retrospectively assessed previously. Baseline measurements prior to switching to EC use were compared to follow-up visits at 12, 24, and 36 months. Age- and sex-matched regularly smoking COPD patients who were not using ECs were included as reference (control) group.Results: Com